ASLAN Pharmaceuticals is a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients.
Our senior management team has extensive experience in global and regional development and commercialisation and an aggregate of over 70 years of experience working in Asia.
We focus on Asia prevalent tumour types, including biliary tract cancer, gastric cancer and breast cancer. As few effective therapies exist to treat these diseases, there is a significant unmet need globally.
Founded in 2010, ASLAN has rapidly established a strong track record in oncology-focused product development. Since our founding, we have raised over US$167 million in financing, formed innovative partnerships with pharmaceutical industry leaders and developed four therapeutic medicines that target cancers for which there are few effective treatments.